Chitin: A Comprehensive Reference
1. Identity, Chemical Nature, and Natural Sources
Chitin (pronounced KY-tin) is one of the most abundant naturally occurring biopolymers on Earth. It is a linear polymer composed of N-acetylglucosamine residues linked by β-(1,4)-glycosidic bonds. Chitin has the chemical formula (C₈H₁₃O₅N)ₙ. Its structure is most similar to that of cellulose, while its function is most similar to that of keratin. Chitin has an acetamide group at the C2 position instead of a hydroxyl group within the glucose unit. This nitrogen-containing substitution distinguishes chitin from cellulose and is responsible for many of its unique biological properties.
Microfibrils of chitin are structural components found throughout invertebrates, including sponge skeletal fibers, mollusk shells, nematode eggshells and pharynxes, crustacean shells, arthropod exoskeletons, and fungi cell walls, forming natural biocomposites. Insect exoskeletons are made of a composite of chitin and sclerotin, a matrix of proteins. The shells of crustaceans are usually made of chitin and calcium carbonate.
In terms of commercial and dietary relevance, over 90% of commercial chitin is derived from the shells of crustaceans, highlighting its abundant availability in nature. Shrimp (Pandalus borealis, Penaeus spp.), crabs, lobsters, krill, and crayfish are the principal commercial sources. Fungal chitin from species such as Aspergillus niger, yeasts, and various mushrooms represents an important alternative, particularly for products intended for individuals with shellfish sensitivities. It is particularly advantageous to obtain chitin and chitosan from insects, as the latter represent an abundant and renewable raw material.
Common Forms and Preparations
Chitin as an isolated ingredient is generally insoluble in water and most organic solvents. For most health and supplemental applications, it is commercially processed into its primary derivative, chitosan. Chitosan is commercially produced by soaking crustacean shells with sodium hydroxide, a highly alkaline substance to remove the acetyl groups (COCH₃) in chitin. This chemical deacetylation converts the insoluble chitin polymer into a more soluble and bioactive fiber. Its chemical structure can most simply be described as a co-polymer of glucosamine and acetyl-glucosamine.
Both chitin and chitosan are available in several physical forms for dietary, pharmaceutical, and topical uses. Food supplement preparations include capsules, tablets, and powders that often combine chitosan with other micronutrients to maximize its beneficial effects; dietary products are specifically formulated for weight management, where chitosan is the main ingredient; there are also chitosan-enriched foods that can be integrated into the daily diet. Additional pharmaceutical-grade forms include films, hydrogels, sponges, membranes, nanoparticles, and wound dressings.
The applications of chitin and/or chitosan are numerous: cosmetic, medical and pharmaceutical (pharmaceutical compositions, treatment for burns, biomaterials, corneal dressings, surgical threads), dietary and food, and technical (filtering, texturing, flocculating or adsorbing agents, in particular for water filtration).
2. Historical and Traditional Use
Scientific Discovery
The word "chitin" is derived from the Greek etymology, meaning "tunic" or "envelope." Although the first mention of calcified chitin in invertebrates was made by Hatchett in 1799, the discovery of chitin is usually attributed to Braconnot in 1811, who discovered chitin from fungi, and to Odier in 1823, who obtained a hornlike material after treatment of cockchafer elytra with potassium hydroxide. Chitin was first named fongine by Braconnot and then chitine by Odier. Children revealed the nitrogenous nature of chitin in 1824. The history of chitosan, the main derivative of chitin, dates back to 1859 with the work of Rouget. The name "chitosan" was introduced in 1894 by Hoppe-Seyler.
In the 1930s and 1940s, polymers attracted considerable attention, as evidenced by about 50 patents secured during that time. Lack of adequate manufacturing facilities and cut-throat competition from synthetic polymer producers restricted commercial development. Revived interest in the 1970s encouraged the need to better utilize shellfish shells.
Traditional Dietary Exposure
Formal chitin supplementation as a distinct health practice is a modern development with no documented pre-industrial ethnobotanical tradition of intentional chitin dosing. However, dietary exposure to chitin has occurred throughout human history through the consumption of shellfish and insects. The consumption of insects in Latin America dates back to pre-Columbian times when indigenous people like the Aztecs and Mayans included them as a key part of their diet. Today, many of these traditions continue, especially in Mexico, where insects are considered a delicacy and a symbol of cultural heritage. Chapulines, or grasshoppers, are a well-known street food in Mexico, often seasoned with chili, garlic, and lime. A previous study referenced in the scientific literature estimated 3,000 ethnic groups in 130 countries eat insects mostly harvested in the wild. Through these practices, populations have historically consumed meaningful quantities of dietary chitin, though it was not isolated or intentionally administered as a supplement until the modern era.
The modern commercial development of chitosan as a dietary supplement emerged primarily in Japan during the 1980s and 1990s, and subsequently spread to global markets. Its use as a weight management and cholesterol-lowering supplement gained regulatory and public attention in the late 20th century following renewed interest in natural fibers.
3. Key Constituents and Mechanisms of Action
Structural Properties
Chitin (C₈H₁₃O₅N)ₙ is a modified polysaccharide (poly-beta-1,4-N-acetylglucosamine) containing nitrogen with a structure analogous to indigestible cellulose; it is considered an insoluble fiber with potential prebiotic properties that could benefit human health by selectively promoting the growth of beneficial bacterial species in the intestines, though this relationship is not well understood.
Insoluble fibers such as chitin are indigestible in the human gastrointestinal tract. They are essential for increasing stool bulk and softness, which helps promote regular bowel movements and reduce intestinal transit time.
Lipid-Binding and Fat Absorption
The most extensively studied mechanism of chitosan (the primary active derivative of chitin in oral supplementation) involves lipid binding in the gastrointestinal tract. Positively charged amino groups in chitosan bind to negatively charged lipid and bile components, preventing their absorption by the body. Cholesterol-lowering properties are due to the hydrophobic bonds it forms with cholesterol and other sterols, interfering with the emulsification process. A beneficial effect of chitin-chitosan as a food supplement is the reduction of plasma cholesterol and triglycerides due to its ability to bind dietary lipids. Bile acid composition and short-chain fatty acid content in the cecum are altered by chitosan, which impedes lipid emulsification and absorption.
Immune Modulation
Mammals are potential hosts for chitin-containing protozoa, fungi, arthropods, and nematodes; however, mammals themselves do not synthesize chitin and thus it is considered a potential target for recognition by the mammalian immune system. Chitin is sensed primarily in the lungs or gut, where it activates a variety of innate (eosinophils, macrophages) and adaptive immune cells (IL-4/IL-13 expressing T helper type-2 lymphocytes). Chitin induces cytokine production, leukocyte recruitment, and alternative macrophage activation.
Structural chitin present in microorganisms is actively degraded by host true chitinases, including acidic mammalian chitinases and chitotriosidase, into smaller fragments that can be sensed by mammalian receptors such as FIBCD1, NKR-P1, and RegIIIc. Immune recognition of chitin also involves pattern recognition receptors, mainly via TLR-2 and Dectin-1, to activate immune cells to induce cytokine production and creation of an immune network that results in inflammatory and allergic responses.
Chitin's interaction with the immune system is context-dependent and complex. NOD-2 and TLR-9 recognize chitin and act together to mediate an anti-inflammatory response via secretion of the cytokine interleukin (IL)-10.
Prebiotic Activity in the Gut
Several in vitro and in vivo studies have shown the possible microbiota modulation of chitin and its relevant communication with the immune system, thus confirming its prebiotic activity. Chitosan's prebiotic effects are linked to selectively stimulating beneficial gut bacteria, such as Bifidobacteria and Lactobacillus, while enhancing gut barrier integrity and inhibiting the growth of pathogenic microorganisms.
Wound Healing and Hemostasis
The high positive charge on chitosan can stimulate erythrocyte adhesion, fibrinogen adsorption, and platelet activation, rendering it an excellent hemostatic agent. Chitosan is permeable to oxygen, promotes immunity, and exhibits characteristics of high biocompatibility and biodegradability, non-antigenicity, low toxicity, and antimicrobial efficacy, indicating its potential in tissue engineering and biomedical applications.
Chitin and chitosan are biopolymers with excellent bioactive properties, such as biodegradability, non-toxicity, biocompatibility, haemostatic activity, and antimicrobial activity. A wide variety of biomedical applications for chitin and chitin derivatives have been reported, including wound-healing applications.
4. Scientific Evidence by Area of Use
4.1 Body Weight and Obesity
This is the most extensively studied clinical application of chitosan (deacetylated chitin) as a dietary supplement. The evidence is mixed, with clear discrepancies between lower-quality and higher-quality trials.
A systematic review by Ni Mhurchu included 14 randomised placebo-controlled clinical trials with a total of 1,131 participants assessing chitosan as a weight reduction agent. The duration of studies ranged from 4–24 weeks. The results showed a slight reduction in weight compared with placebo. Analyses involving all trials in that review indicated that chitosan preparations result in a small but statistically significant greater reduction in body weight (weighted mean difference −1.7 kg; 95% confidence interval −2.1, −1.3 kg, P < 0.00001) compared with placebo.
However, the Cochrane Collaboration has provided the most authoritative assessment. Results obtained from high-quality trials indicate that the effect of chitosan on body weight is minimal and unlikely to be of clinical significance. Fifteen studies lasting between 4 to 24 weeks, including a total of 1,219 participants, were analyzed. Trials of chitosan to date have varied considerably in terms of quality. The review suggests that chitosan may have a small effect on body weight, but results from high-quality trials indicate that this effect is likely to be minimal.
Reviews from 2016 and 2008 found there was no significant effect, and no justification for overweight people to use chitosan supplements.
A 2024 systematic review and meta-analysis found some suggestion that chitosan supplementation may improve obesity indicators by decreasing body fat percentage and increasing fat-free mass; however, well-methodological studies with greater sample sizes are still needed to verify the obtained results.
Evidence strength: Weak to modest. Statistically significant effects in aggregate analyses but clinically negligible reductions in high-quality trials. The overall evidence does not support chitosan as a clinically meaningful weight-loss intervention.
4.2 Blood Lipids and Cardiovascular Risk Factors
A meta-analysis comparing and reviewing 15 randomised controlled trials reported evidence that chitosan was more effective than a placebo in the treatment of overweight and obesity, high blood pressure, and slightly effective for lowering total cholesterol and triglycerides. The study included 1,219 patients with treatment duration of 4–24 weeks.
A more recent (2025) systematic review and meta-analysis of randomised controlled trials examining lipid parameters reached a more conservative conclusion: chitosan produced clinically insignificant reductions in LDL-C and total cholesterol. Chitosan showed negligible effects on triglycerides, with no clinical relevance. No significant improvement was observed in HDL-C with chitosan use. The certainty of evidence was low to moderate, requiring larger and more robust trials.
With respect to blood pressure, a systematic review provided evidence that chitosan significantly lowered systolic blood pressure (WMD: −6 mmHg, 95% CI: −7 to −5) and diastolic blood pressure (WMD: −3 mmHg, 95% CI: −4 to −2). Heterogeneity was noted for these outcomes (for SBP, I²=78.5%; for DBP, I²=86.3%).
A study on the impact of chitin-glucan derived from Aspergillus niger mycelium on oxidized low-density lipoprotein (OxLDL) in adults—a risk factor for atherosclerosis—found that chitin-glucan intakes of 4.5 g/day significantly reduced OxLDL in 6 weeks.
Evidence strength: Low to moderate. Statistically measurable effects on LDL, total cholesterol, and blood pressure have been documented in meta-analyses, but effect sizes are small and clinical significance is disputed. High heterogeneity across trials is a limitation.
4.3 Gut Microbiota and Prebiotic Effects
Laboratory, animal, and human studies indicate that insect fiber in the form of chitin and its derivatives can modify gut microbiota with beneficial outcomes. Some insects also contain favorable omega-3/omega-6 ratios.
Evidence shows that cricket chitin enhanced the growth of Bifidobacterium animalis and Lactobacillus rhamnosus GG. A notable human study showed that chitin consumption (2–5 g/day for 3 weeks) fosters beneficial bacterial genera such as Roseburia and Eubacterium, elevates short-chain fatty acid production, including butyrate, and enhances gut microbiota diversity.
Apart from containing a high protein content, insects also have dietary fiber in the form of chitin, which helps to enrich gut microbiota. Chitin enhances the production of short-chain fatty acids that benefit the microbiome and seems to be linked to intestinal immunity.
However, gaps in the literature—especially a dearth of human studies—must be addressed to better understand the health impacts of insect chitin consumption. A study of chito-oligosaccharides found that chitosan derivatives from shrimp with a high content of acetylated residues did not cause a putatively prebiotic effect in human gut microbiota, although this study was conducted on human fecal microbiota in batch cultures and not in humans directly.
Evidence strength: Preliminary. Most evidence comes from in vitro, animal, and small human studies. Human intervention data are limited but suggest a plausible prebiotic effect. Chitin particle size and degree of acetylation appear to influence outcomes.
4.4 Wound Healing and Hemostasis (Topical/Biomedical)
Chitin, a unique biopolymer based on the N-acetyl-glucosamine monomer, is envisioned to promote rapid dermal regeneration and accelerate wound healing. It has many useful and advantageous biological properties for its application as a wound dressing. Chitin dressings provide an effective barrier to microbial penetration and exert broad bacteriostatic action against Gram-positive and Gram-negative organisms.
Chitosan, a polysaccharide derived from chitin, has excellent wound healing properties, including intrinsic antimicrobial and hemostatic activities. These properties have led to its incorporation in approved wound care products and military hemostatic bandages. Other medical uses reported for chitin and chitosan are antibacterial sponges and hospital dressings, dental plaque inhibition, artificial blood vessels, inhibition of tumor cells, and reduction of blood cholesterol levels.
Despite significant advancements, there remains a critical gap in translating chitosan-based biomaterials from research to clinical applications.
Evidence strength: Moderate for topical/wound-care applications, particularly hemostasis, which has been validated in pre-clinical and some clinical settings. Approved chitosan-based hemostatic dressings exist in multiple countries. Oral wound-healing evidence is limited.
4.5 Immune System Modulation
Chitin is known to modulate various aspects of both innate and adaptive immunity, reflecting the conservation of ancient recognition pathways likely tied to the recognition of fungi and/or ectoparasites. Administration of chitin microparticles (CMPs) improves the outcome of experimentally induced colitis and can modulate immune responses during intestinal inflammation.
Chitin has been reported to have anti-ulcer, anti-tumor, and anti-inflammatory properties in preclinical models. No evidence has been provided on the carcinogenic activity of chitin; however, studies have suggested that chitin has a cytotoxic effect on cancer cell lines.
Evidence strength: Preclinical (animal and in vitro). The immunological effects of chitin are well-characterized in animal models but lack robust human clinical evidence. Effects appear to depend heavily on chitin particle size, acetylation degree, and route of administration.
4.6 Antimicrobial Activity
Chitin-chitosan inhibits in vitro growth of microorganisms including Candida, and in vivo has a protective effect on Candida infection. The antibacterial and antiyeast activities of chitosan are desirable properties and may be useful in preventing infection of wounds by direct application.
As a natural cationic biopolymer in its dissolved form (pH <5.7), chitosan possesses a positive charge, giving rise to versatile uses based on its antimicrobial, gelling, and film-forming properties.
Evidence strength: In vitro and animal evidence is consistent for antimicrobial activity. Direct human evidence for systemic antimicrobial benefit from dietary chitin intake is absent.
5. Body Systems and Health Areas
- Gastrointestinal system: Acts as insoluble dietary fiber; influences stool bulk and transit time; modulates gut microbiota composition; may have prebiotic effects; investigated in inflammatory bowel conditions.
- Cardiovascular system: Studied for effects on total cholesterol, LDL, triglycerides, and blood pressure via lipid-binding and fat excretion mechanisms.
- Immune system: Recognized by multiple pattern-recognition receptors; modulates macrophage polarization, cytokine profiles, and T-helper cell responses; investigated as an immunoadjuvant.
- Integumentary system (skin): Used topically in wound dressings, hydrogels, and films for hemostasis, antimicrobial protection, and tissue regeneration.
- Metabolic/endocrine: Investigated in the context of metabolic syndrome, obesity, and dyslipidemia.
- Renal system: Some studies have investigated chitosan supplementation in the context of hemodialysis patients and kidney function, though evidence remains preliminary.
6. Dosage Forms and Reported Dosages
Clinical trials of chitosan for weight and lipid outcomes have typically lasted between 4 to 24 weeks and included a total of 1,219 participants.
In terms of specific dosages reported in the scientific literature:
- Chitin consumption at 2–5 g/day for 3 weeks was studied in relation to gut microbiota changes, fostering beneficial bacterial genera and elevating short-chain fatty acid production.
- Chitin-glucan from Aspergillus niger at a dose of 4.5 g/day significantly reduced oxidized LDL in 6 weeks.
- Chitosan doses in weight-loss and lipid trials across reviewed systematic reviews ranged broadly, with durations of 4 to 24 weeks, reflecting substantial heterogeneity in commercial preparations.
Dosage forms used in clinical research and commercially available products include capsules, tablets, and powders, often combined with other micronutrients. Chitin-glucan from fungal sources has also been used in capsule form in human trials. For topical/biomedical applications, chitin is formulated as membranes, films, hydrogels, sponges, and bandages.
No standardized therapeutic dosage for dietary chitin or chitosan has been established by any major regulatory body. Chitin-glucan from Aspergillus niger has received Novel Food authorization in the European Union.
7. Safety Considerations and Interactions
General Tolerability
Common side effects of chitosan include constipation, flatulence (gas), bloating, nausea, and abdominal cramping. Adverse effects were associated with high intakes in clinical studies, which were typically mild symptoms of gastrointestinal tract distress such as diarrhoea, bloating, or vomiting. Chitosan induces constipation, an undesirable condition that includes difficult and often painful elimination, in some users.
Shellfish Allergy
One of the important issues for human health is the correlation between chitin and the immune response. The immune system considers chitin a non-self element, resulting in a wide spectrum of potential symptoms. However, the immune response occurs in predisposed individuals or those particularly exposed to massive allergen doses for a prolonged period.
A reported case of immediate-type allergy was most likely due to residual protein from the shellfish source from which the chitosan supplement was derived. Severe seafood allergy is usually mediated by the major shellfish allergen tropomyosin, which is not present in purified chitosan. Despite this distinction, people with shellfish allergies are advised to avoid products containing chitin or chitosan, as these may be contaminated with shellfish proteins.
In a small clinical study examining shellfish-allergic individuals' tolerance of chitosan-containing wound dressings, no participant had a positive skin prick test to chitosan powder or experienced an adverse reaction during bandage challenges. No protein bands were visualized during gel electrophoresis analysis of chitosan powder. The study authors concluded that all participants tolerated the chitosan bandage without reaction. Nonetheless, this was a small sample and should not be generalized without further study.
Nutrient and Mineral Absorption
A significant safety concern with chitosan's fat-binding mechanism is its potential to impair absorption of fat-soluble vitamins and minerals. Chitosan acts by forming gels in the intestinal tract which entrap lipids and other nutrients, including fat-soluble vitamins and minerals, thus interfering with their absorption. Chitosan may also prevent the body from absorbing fat-soluble vitamins such as vitamins A, D, E, and K. Magnesium may also not be absorbed.
Animal studies have quantified this concern: rats fed chitosan showed significantly lower apparent fat digestibility than controls. Chitosan feeding for 2 weeks caused a decrease in mineral absorption and bone mineral content. Moreover, ingestion of chitosan along with ascorbate led to a marked and rapid decrease in serum vitamin E levels.
While no long-term studies of the effects of chitosan on human health have been done, animal studies suggest that this compound could inhibit the absorption of minerals and fat-soluble vitamins.
Drug Interactions
Chitosan can bind to minerals and fat-soluble vitamins, possibly reducing their levels in the body. It can also attach to drugs and reduce their effectiveness. It is prudent to talk with a healthcare professional before taking chitosan if taking any medications, including blood thinners. Chitosan may have a negative interaction with medications like warfarin.
Pregnancy and Long-Term Use
No adequate long-term human safety data exist for oral chitin or chitosan supplementation. The use of chitosan as a dietary supplement must be of short duration, or other ingredients or supplements must be added to combat its undesirable effects. Chitin and chitosan are classified by regulatory bodies as generally biocompatible, but formal long-term toxicity data in humans are lacking.
References
Go back